Published in Gastroenterol Clin North Am on June 01, 2004
Optimising corticosteroid treatment for autoimmune pancreatitis. Gut (2007) 1.01
Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J Gastroenterol (2008) 0.96
Use of thiopurines in inflammatory bowel disease. World J Gastroenterol (2013) 0.89
Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data. Patient (2013) 0.87
Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: Our experience with a prospective study. World J Gastroenterol (2006) 0.86
Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease. World J Gastroenterol (2008) 0.78
Azathioprine in the management of enteropathy in cystic fibrosis. J R Soc Med (2011) 0.75
Start low, go slow, but don't go this way yet. Can J Gastroenterol (2008) 0.75
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology (2004) 4.26
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology (2013) 3.28
Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol (2002) 3.01
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc (2006) 2.73
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology (2007) 2.55
Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol (2004) 2.45
Idiopathic gastric acid hypersecretion presenting as a diarrheal disorder and mimicking both Zollinger-Ellison syndrome and Crohn's disease. Eur J Gastroenterol Hepatol (2005) 2.15
Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology (2006) 2.14
Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis (2008) 2.04
Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology (2003) 1.94
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol (2003) 1.72
A randomized, controlled, double-blind trial of patient-controlled sedation with propofol/remifentanil versus midazolam/fentanyl for colonoscopy. Anesth Analg (2008) 1.71
Heterotopic pancreas presenting as dysphagia. Am J Gastroenterol (2002) 1.63
A prospective, randomized, comparative trial evaluating respiratory depression during patient-controlled versus anesthesiologist-administered propofol-remifentanil sedation for elective colonoscopy. Gastrointest Endosc (2010) 1.57
A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2010) 1.55
A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology (2004) 1.51
Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am (2002) 1.49
A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology (2006) 1.39
Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol (2003) 1.35
The impact of increased body mass index on the clinical course of Crohn's disease. Clin Gastroenterol Hepatol (2006) 1.32
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis (2011) 1.22
The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol (2011) 1.15
Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis (2009) 1.15
Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology (2013) 1.14
Complications of biological therapy for inflammatory bowel diseases. Curr Opin Gastroenterol (2006) 1.12
Seasonal variation in flares of inflammatory bowel disease. Gastroenterology (2004) 1.10
Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis (2008) 1.09
No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease. Clin Gastroenterol Hepatol (2011) 1.05
An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial. Clin Gastroenterol Hepatol (2005) 1.03
Corticosteroids in Crohn's disease. Am J Gastroenterol (2002) 0.99
Methods to avoid infections in patients with inflammatory bowel disease. Inflamm Bowel Dis (2005) 0.98
The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease. Ann N Y Acad Sci (2006) 0.98
Infliximab in fistulizing Crohn's disease. Gastroenterol Clin North Am (2006) 0.94
What is the optimal therapy for Crohn's disease: step-up or top-down? Expert Rev Gastroenterol Hepatol (2010) 0.94
Colonic dysplasia and cancer in inflammatory bowel disease. Gastrointest Endosc Clin N Am (2002) 0.94
Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol (2010) 0.93
Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol (2006) 0.92
Clinical pharmacology of 5-ASA compounds in inflammatory bowel disease. Gastroenterol Clin North Am (2010) 0.91
Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am (2006) 0.91
Current and Future Anti-TNF Therapy for Inflammatory Bowel Disease. Curr Treat Options Gastroenterol (2007) 0.90
Safety of biologic therapy. Inflamm Bowel Dis (2007) 0.89
Antibiotic use and the risk of flare of inflammatory bowel disease. Clin Gastroenterol Hepatol (2005) 0.88
Risk for active tuberculosis in inflammatory bowel disease patients. Clin Gastroenterol Hepatol (2007) 0.86
Clinical predictors of aggressive/disabling disease: ulcerative colitis and crohn disease. Gastroenterol Clin North Am (2012) 0.86
Hepatosplenic T-cell lymphoma in inflammatory bowel disease: a possible thiopurine-induced chromosomal abnormality. Am J Gastroenterol (2010) 0.85
Update on the management of Crohn's disease. Curr Gastroenterol Rep (2011) 0.85
Optimizing therapy in patients with pancolitis. Inflamm Bowel Dis (2005) 0.85
Inflammatory bowel disease therapy: current state-of-the-art. Curr Opin Gastroenterol (2011) 0.85
Treatment of ulcerative colitis. Curr Opin Gastroenterol (2014) 0.83
Crohn's disease in the ileal pouch after total colectomy for ulcerative colitis: findings on pouch enemas in six patients. AJR Am J Roentgenol (2005) 0.83
Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol (2013) 0.83
Are there predictors of Remicade treatment success or failure? Adv Drug Deliv Rev (2005) 0.83
Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitis. Liver Int (2005) 0.82
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. Gastroenterology (2003) 0.82
Infliximab in ulcerative colitis. Gastroenterol Clin North Am (2006) 0.82
Colorectal cancer in inflammatory bowel disease. Curr Opin Gastroenterol (2004) 0.82
Recent developments in inflammatory bowel disease. Med Clin North Am (2002) 0.81
Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol (2014) 0.80
Incorrect cost of infliximab in fistulizing Crohn's disease. Gastroenterology (2004) 0.80
Nutrition in Crohn disease. Curr Opin Gastroenterol (2003) 0.80
Therapy of inflammatory bowel disease: what to expect in the next decade. Curr Opin Gastroenterol (2014) 0.79
Measurement of Inflammatory Bowel Disease Symptoms: Reliability of an Abbreviated Approach to Data Collection. Inflamm Bowel Dis (2015) 0.79
Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf (2014) 0.79
What next after infliximab? Am J Gastroenterol (2005) 0.78
Is dysplasia visible during surveillance colonoscopy in patients with ulcerative colitis? Scand J Gastroenterol (2008) 0.78
Infliximab use in Crohn's disease. Expert Opin Biol Ther (2005) 0.78
The NOD2 gene and Crohn's disease: another triumph for molecular genetics. Gastroenterology (2002) 0.78
How to Assess and Document Endoscopies in IBD Patients by Including Standard Scoring Systems. Inflamm Bowel Dis (2016) 0.77
Safety of biologics in inflammatory bowel disease. Curr Treat Options Gastroenterol (2006) 0.77
Treatment of fistulizing Crohn's disease. Gastroenterol Clin North Am (2004) 0.77
Evaluation of polypoid lesions in inflammatory bowel disease. Gastrointest Endosc Clin N Am (2002) 0.77
The influence of anti-TNF therapy on the course of chronic hepatitis C virus infection in patients with inflammatory bowel disease. Dig Dis Sci (2012) 0.77
Mesalamine with MMX technology for the treatment of ulcerative colitis. Expert Rev Gastroenterol Hepatol (2008) 0.77
High-grade dysplastic adenoma-like mass lesions are not an indication for colectomy in patients with ulcerative colitis. Scand J Gastroenterol (2008) 0.77
5-ASA Dose-Response: Maximizing Efficacy and Adherence. Gastroenterol Hepatol (N Y) (2010) 0.76
Papillary thyroid cancer and inflammatory bowel disease: is there a relationship? World J Gastroenterol (2013) 0.76
Recent developments in the pharmacological treatment of Crohn's disease. Expert Opin Investig Drugs (2004) 0.76
Maintenance infliximab therapy in patients with Crohn's disease: how long, how much, how frequent? Gastroenterology (2003) 0.75
Impact of JC virus antibody testing in patients with Crohn's disease with loss of response to infliximab: a Markov model. Inflamm Bowel Dis (2013) 0.75
Infliximab treatment of postoperative ulcers in Crohn's disease: to inject or not to inject--that is the question. Gastrointest Endosc (2006) 0.75
Response to Dr Waldum's letter regarding 'Idiopathic gastric acid hypersecretion presenting as a diarrheal disorder and mimicking both Zollinger-Ellison syndrome and Crohn's disease'. Eur J Gastroenterol Hepatol (2005) 0.75
Survival in elderly patients with ulcerative colitis and colorectal cancer. Dig Dis Sci (2012) 0.75
Letter from the editor. Gastroenterol Hepatol (N Y) (2014) 0.75
Letter from the editor. Gastroenterol Hepatol (N Y) (2014) 0.75
Letter from the editor. Gastroenterol Hepatol (N Y) (2013) 0.75
Letter from the editor. Gastroenterol Hepatol (N Y) (2013) 0.75
Letter from the editor. Gastroenterol Hepatol (N Y) (2013) 0.75
Letter from the editor. Gastroenterol Hepatol (N Y) (2013) 0.75
Letter from the editor. Gastroenterol Hepatol (N Y) (2013) 0.75
Letter from the editor. Gastroenterol Hepatol (N Y) (2014) 0.75
Fall Conferences. Gastroenterol Hepatol (N Y) (2017) 0.75
Letter from the editor. Gastroenterol Hepatol (N Y) (2014) 0.75
Letter from the editor. Gastroenterol Hepatol (N Y) (2014) 0.75
Letter from the editor. Gastroenterol Hepatol (N Y) (2014) 0.75
Letter from the editor. Gastroenterol Hepatol (N Y) (2013) 0.75